tracking blood pressure and subclinical CAD

The CARDIA study of 3442 black and white men and women aged 18-30 in 4 cities (Birmingham AL, Chicago IL, Minneapolis MN, Oakland CA) were followed 25 years (1985-2010), and were assessed for BP measured at baseline, 2,5,7,10,15,20, and 25 years, then evaluated for subclinical CAD by their coronary artery calcification (CAC), perhaps the best predictor of atherosclerotic disease (confirmed in the recent AHA guidelines) -- (see htn young and CAD middleage jama 2104 in dropbox, or doi:10.1001/jama.2013.285122). they assessed 5 different BP trajectories, with the following adjusted odds ratios for high CAC score (comparing the 4 other categories with the low-stable cohort):

--low-stable bp (19.9% of population), with SBP 101-104, DBP 62-64 over the 25 yrs -- this group had an elevated CAC score developing in 5.8%
--moderate-stable (42.3%), with SBP 109-118, DBP 68-74 over the 25 yrs -- odds ratio 1.44, with absolute increase above the low-stable group of 2.7% (not reaching statistical significance)
--moderate-increasing (12.2%), with SBP 111-142, DBP 69-89 over the 25 yrs -- odds ratio 1.86, with absolute increase above the low-stable group of 5% (not reaching statistical significance)
--elevated-stable (19%), with SBP 120-123, DBP 76-77 over the 25 yrs -- odds ratio 2.28, with absolute increase above the low-stable group of 6.3%
--elevated-increasing (4.8%), with SBP 125-146, DBP 80-92 over the 25 yrs -- odds ratio 3.70, with absolute increase above the low-stable group of 12.9%
--more of the low-stable group with female, white, more educated, and fewer concurrent cardiovasc risk factors
--rapid increases in BP more in African-American men, also with higher rates of smoking, and more increases in BMI. Af-Amer women more represented in the moderate-increasing group.  only minimal changes in above risks for increased CAC after controlling for demographics, other cardiovasc risk factors, or use of antihypertensive meds.

so, interesting to see longitudinal data of individuals, instead of just cross-sectional data. most of the individuals were within the "pre-hypertensive" category. this study strongly reinforces assessing blood pressure regularly and promoting healthy lifestyle in younger people (though this was not an intervention study of lifestyle changes, it certainly makes sense to inform pre-hypertensive individuals, and esp those with increasing blood pressure, that they are at increased risk of CAD and that it would be prudent to decrease this risk through targeted lifestyle interventions).

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more